Conduit Pharmaceuticals Inc. has entered into a joint development agreement with Manoira to advance the development of AZD1656 and AZD5658 in the animal health sector. This collaboration aims to leverage Manoira's expertise in reformulation to generate cross-species insights, accelerating the progression of human clinical programs and tapping into the estimated $15 billion animal health market. The agreement emphasizes a cost-efficient approach that enhances Conduit's pipeline while maintaining full ownership of intellectual property. This partnership underscores Conduit's strategy of innovative collaborations, seeking to redefine treatment standards in both veterinary and human applications. Under the terms, Conduit will issue Manoira $500,000 in common stock, while Manoira will fund all development activities.